Get to know our clinical trials

Clinical trial to evaluate the safety, pharmacokinetics, and efficacy of daily intravenous administration of AB8939 in patients with relapsed/refractory acute myeloid leukemia

THE AIM OF THIS STUDY IS TO DETERMINE THE EFFICACY AND SAFETY OF THE INVESTIGATIONAL DRUG AB8939 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR REFRACTORY MYELODYSPLASTIC SYNDROME.

Imagen de la Dra. Ana Alfonso Piérola, especialista en Hematología de la Clínica Universidad de Navarra. La Dra. Alfonso se dedica al estudio y tratamiento de los síndromes mielodisplásicos y las leucemias mieloblásticas agudas.
Dr. Ana Alfonso Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF DAILY INTRAVENOUS ADMINISTRATION OF AB8939 IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA.
  • Code EudraCT: 2020-005122-28
  • Protocol number: AB18001
  • Promoter: AB Science

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION